SCHEMBL2690901

SCHEMBL2690901

COC(=O)[C@H]1[C@H](C(=O)OC)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.35
CCR6 P51684 1/20 0.35
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
LMNA P02545 2/20 0.33
CHRNB2 P17787 2/20 0.33
CHRNA4 P43681 2/20 0.33
CYP2C19 P33261 1/20 0.33
POLA1 P09884 1/20 0.33
GAA P10253 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
CYP1A2 P05177 1/20 0.32
HIF1A Q16665 1/20 0.32
MMP2 P08253 1/20 0.32
ANPEP P15144 1/20 0.32
ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2690897 1.00 HTT (0.35) HTTCCR6ALDH1A1KMT2AATM
SCHEMBL2690895 1.00 HTT (0.35) HTTCCR6ALDH1A1KMT2AATM
SCHEMBL27811564 0.90 ALDH1A1 (0.35) HTTCCR6ALDH1A1KMT2AATM
SCHEMBL10692865 0.90 PPM1B (0.35) HTTCCR6ALDH1A1KMT2AATM
SCHEMBL1261691 0.90 PPM1B (0.35) HTTCCR6ALDH1A1KMT2AATM
SCHEMBL10329694 0.90 PPM1B (0.35) HTTCCR6ALDH1A1KMT2AATM
SCHEMBL11134886 0.88 ATM (0.33) HTTCCR6KMT2AATMCHRNB2
Hydrochloric Acid SCHEMBL11134893 0.88 PPM1B (0.34) HTTCCR6ALDH1A1KMT2AATM
SCHEMBL12609929 0.86 ATM (0.36) HTTCCR6ALDH1A1ATMLMNA
SCHEMBL11006784 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1970369-B1 METHOD FOR PRODUCING PURIFIED FORMYLCYCLOPROPANE COMPOUND AND INTERMEDIATE OF SUCH FORMYLCYCLOPROPANE COMPOUND SUMITOMO CHEMICAL CO (JP) 2013-09-25 EP disclosed
US-8168816-B2 Method for producing purified formylcyclopropane compound and intermediate of such formylcyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-01 US disclosed
US-20100305353-A1 METHOD FOR PRODUCING PURIFIED FORMYLCYCLOPROPANE COMPOUND AND INTERMEDIATE OF SUCH FORMYLCYCLOPROPANE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-12-02 US disclosed
EP-1970369-A1 METHOD FOR PRODUCING PURIFIED FORMYLCYCLOPROPANE COMPOUND AND INTERMEDIATE OF SUCH FORMYLCYCLOPROPANE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305353-A1 METHOD FOR PRODUCING PURIFIED FORMYLCYCLOPROPANE COMPOUND AND INTERMEDIATE OF SUCH FORMYLCYCLOPROPANE COMPOUND FPR1, FPR2, DHPS HTT 2139/4885CCR6 83/4885ALDH1A1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.